In fact, inhibitors of phosphodiesterase 9 were found to induce phosphorylation of HspB6 and reduce Aβ cellular toxicity (Cameron et al., 2017); one of these compounds is currently being tested in an AD clinical trial (NCT00930059). This evidence concerns the gene HSPB6 and Alzheimer disease.